Publication Name	World Journal of Hepatology
Manuscript ID	89628
Country	China

Category	Infectious Diseases
Manuscript Type	Retrospective Study
Article Title	Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy
Manuscript Source	Unsolicited Manuscript
All Author List	Pei-Xin Zhang, Xiao-Wei Zheng, Ya-Fei Zhang, Jun Ye, Wei Li, Qian-Qian Tang, Jie Zhu, Gui-Zhou Zou and Zhen-Hua Zhang
Funding Agency and Grant Number	Funding Agency Grant Number Anhui Provincial Natural Science Foundation 2108085MH298 Scientific Research Project of the Second Affiliated Hospital of Anhui Medical University 2019GMFY02, 2021lcxk027 Scientific Research Project of Colleges and Universities in Anhui Province KJ2021A0323
Corresponding Author	Zhen-Hua Zhang, MD, Professor, Department of Infectious Diseases, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, Anhui Province, China. zzh1974cn@163.com
Key Words	Chronic hepatitis B; Hepatitis B e antigen-positive; Peginterferon-alfa; Prediction model; Response-guided therapy strategy
Core Tip	This study identified the optimal independent predictors of treatment response in previously treated patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who received peginterferon alpha therapy. Using single-factor and multi-factor logistic regression analyses, scoring prediction models and response-guided therapy strategies were established. These tools offer guidance for physicians to adjust treatment plans for patients who have not achieved HBeAg seroconversion after long-term nucleos(t)ide analog therapy, carrying significant practical implications for alleviating social and medical burdens.
Citation	Zhang PX, Zheng XW, Zhang YF, Ye J, Li W, Tang QQ, Zhu J, Zou GZ, Zhang ZH. Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy. World J Hepatol 2024; 16 (3): 405-417

Received	2023-11-07 13:38
Peer-Review Started	2023-11-07 13:39
To Make the First Decision
Return for Revision	2023-12-07 12:08
Revised	2023-12-27 06:06
Second Decision	2024-02-01 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-02-01 07:10
Articles in Press	2024-02-01 07:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-13 03:03

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com